Overview

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
Gilead Sciences
Treatments:
Ranolazine